CoLucid Pharmaceuticals (NASDAQ: CLCD) and Female Health Company (The) (NASDAQ:VERU) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Valuation and Earnings

This table compares CoLucid Pharmaceuticals and Female Health Company (The)’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
CoLucid Pharmaceuticals N/A N/A N/A ($3.44) N/A
Female Health Company (The) N/A N/A N/A ($0.19) N/A

Risk & Volatility

CoLucid Pharmaceuticals has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Female Health Company (The) has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Profitability

This table compares CoLucid Pharmaceuticals and Female Health Company (The)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CoLucid Pharmaceuticals N/A -83.51% -70.62%
Female Health Company (The) -42.02% -16.78% -10.64%

Insider & Institutional Ownership

64.2% of CoLucid Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.9% of Female Health Company (The) shares are owned by institutional investors. 13.7% of CoLucid Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Female Health Company (The) shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for CoLucid Pharmaceuticals and Female Health Company (The), as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CoLucid Pharmaceuticals 0 3 1 0 2.25
Female Health Company (The) 0 0 2 0 3.00

Summary

Female Health Company (The) beats CoLucid Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

CoLucid Pharmaceuticals Company Profile

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Female Health Company (The) Company Profile

Veru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout and sexual dysfunction. Women’s Health has product candidates for female sexual health, and advanced breast and ovarian cancers. It manufactures, markets and sells the FC2 Female Condom. FC2 provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

Receive News & Ratings for CoLucid Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.